FLEX ADJUVANT PUBLICATIONS & ABSTRACTS
Clinical evidence from FLEX
Evidence / Adjuvant / FLEX
MammaPrint 3-year outcomes with CT with/without anthracycline
ASCO 2024, #511 Presenter: O'Shaughnessy et al.
Read MorePrediction of chemotherapy benefit by MammaPrint®, Audeh et al., Miami Breast 2024
Miami Breast 2024, Poster 29 Authors: Audeh et al.
Read MoreRacial Disparities in HR+HER2- ESBC, Reid et al., SABCS 2023 Abstract
SABCS 2023, PO1-28-01 Authors: Sonya Reid et al.
Read MoreRacial Disparities in Latin American Patients-FLEX, Mazo Canola et al., SABCS 2023 Abstract
SABCS 2023, PS18-04 Authors: Marcela Mazo Canola et al.
Read MoreResponse Predictive Subtypes in Lobular Tumors-FLEX, Mukhtar et al., SABCS 2023 Abstract
SABCS 2023, PO4-02-03 Authors: Mukhtar et al.
Read MoreWhole transcriptome analysis comparing HR+ HER2- breast cancer tumors from patients ≤ 50 years and > 50 years
PUBLICATION: ASCO 2021 Authors Cathy Graham1, Douglas K. Marks2, Nina D’Abreo2, Sami Diab3, Vijayakrishna K. Gadi4, Midas M. Kuilman5, Andrea Menicucci6, Amy M. Truitt6, Shiyu Wang6, Patricia Dauer6, William Audeh6, FLEX Investigators’ Group8 Background Recent prospective clinical trials have demonstrated a differential chemotherapy effect based on age (≤ Read More
ASCO 2020: 8q22 Poster
PUBLICATION: ASCO 20 AUTHORS: Sami Diab, Matei P. Socoteanu, Carlos A. Encarnacion, Cynthia R. C. Osborne, Carolyn B. Hendricks, Kristi McIntyre, Vibha Taneja Thomas, Rajith Bhaskaran, Josien Haan, Lorenza Mittempergher, Andrea Menicucci, William Audeh, Joyce O'Shaughnessy, FLEX Investigators’ Group SUMMARY: Previous studies have shown that CCNE2 expression is higher in Read More
